Bridge Biotherapeutics Inc. and Scripps Research have reportedly formed a two-year research partnership to discover and identify the advanced reactive group that focuses non-cysteine residues to unravel new druggable sites in high-value therapeutic targets.

Under the multi-year partnership agreement, Scripps will perform research and development activities whereas Bridge Biotherapeutics will maintain an exclusive alternative to acquire global patent and license rights from the research program to further develop and promote the technology.

Bridge Biotherapeutics will partner with Benjamin F. Cravatt III, Ph.D., and Phil S. Baran, Ph.D., pioneers in chemical biology and covalent targeting. The company intends to develop advanced therapeutics for high-value targets in the immunology and oncology space. It believes that advanced reactive group chemistries in combination with proteomics can help in attaining this objective. Bridge looks to explore tunable, proprietary ligands for protein degrader applications and the development of covalent drugs.

Dr. Cravatt and Dr. Baran will be the lead investigators on the project. Dr. Baran is hoping to characterize and validate new targeting axes in the immunology and oncology space and eventually provide advanced life-altering therapies.

According to the Executive Vice President of Bridge Biotherapeutics B. Christopher Kim, Ph.D., the research partnership with Scripps Research paves a new way to the activities of drug discovery and development focused on oncogenic mutations.

Kim added that the company intends to develop a tunable and advanced platform to develop highly selective compounds to acknowledge unmet requirements in multiple disease states.

For those unversed, Bridge Biotherapeutics is a publicly-traded biotech firm headquartered in the Republic of Korea with offices in China, and the United States. The company focuses on the discovery and development of advanced therapeutics for disease indications with high unfulfilled medical needs in ulcerative colitis, cancer, and fibrotic diseases.

Some of the products in the company’s pipeline include BBT-877, an advanced autotaxin inhibitor for treating fibrotic diseases like IPF (idiopathic pulmonary fibrosis), BBT-401, a Pellino-1 inhibitor for treating ulcerative colitis, and BBT-176, an effective targeted cancer therapy for NSCLC (non-small cell lung cancer).

Source credit:

https://www.prnewswire.com/news-releases/bridge-biotherapeutics-and-scripps-research-launch-research-collaboration-to-develop-discovery-platform-and-novel-covalent-probes-based-on-chemical-biology-and-chemoproteomics-301475490.html